S1712- A Randomized Phase II Study Of Ruxolitinib (Nsc-752295) In Combination With Bcr-Abl Tyrosine Kinase Inhibitors In Chronic Myeloid Leukemia (Cml) Patients With Molecular Evidence Of Disease
Posted Date: May 13, 2021
- Investigator: Emily Curran
- Specialties: Cancer, Leukemia, Oncology
- Type of Study: Drug
The purpose of this study is to determine how well ruxolitinib phosphate, and bosutnib, dasatinib, or nilotinib, work in treating patients with chronic myeloid leukemia. The primary outcome is to compare the rate of molecular response 4.5 (MR4.5) between the different treatment arms after 12 months of combination therapy.
Criteria:
Must Have Diagnosis Of Chronic Phase Chronic Myeloid Leukemia Without Any History Of Progression To Accelerated Or Blast Phase Cml, Must Have Been Receiving Tki Treatment For Cml For At Least 12 Months, Must Be Currently Receiving Treatment With Bosutini
Keywords:
Leukemia, Myeloid Leukemia, Cml
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com